Evidence map›Paper›PMID 37207311›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2023

[Severe rhabdomyolysis associated with atorvastatin. Case report].

Jorge Medina-Romero, Otoniel Toledo-Salinas, Francisco Javier Reyes-Álvarez, Saira Sanjuana Gómez-Flores

Open access · greenAbstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jorge Medina-RomeroInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades "Dr. Antonio Fraga Mouret", Servicio de Cardiología. Ciudad de México, México.ORCID 0000-0002-2425-1264
Otoniel Toledo-SalinasInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades "Dr. Antonio Fraga Mouret", Unidad de Cuidados Intensivos. Ciudad de México, México.ORCID 0000-0003-1459-4527
Francisco Javier Reyes-ÁlvarezInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades "Dr. Antonio Fraga Mouret", Servicio de Cardiología. Ciudad de México, México.ORCID 0000-0003-0564-7287
Saira Sanjuana Gómez-FloresInstituto Mexicano del Seguro Social, Centro Médico Nacional "La Raza", Hospital de Especialidades "Dr. Antonio Fraga Mouret", Unidad de Cuidados Intensivos. Ciudad de México, México.ORCID 0000-0002-3820-1938
Centro Médico Nacional La Raza · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dyslipidemia is a risk factor for the development of atherosclerosis and ischemic heart disease. Statins are safe drugs that are part of the routine treatment in patients with Acute Myocardial Infarction (AMI), however, rhabdomyolysis associated with severe myonecrosis due to statins can occur and associated complications such as acute kidney injury increase mortality. The main objective of this article is to report the case of a critically ill patient with AMI who presented severe statin-associated rhabdomyolysis documented with muscle biopsy. Description of the case: A 54-year-old man who presented with AMI, cardiogenic shock, and cardiorespiratory arrest requiring cardiopulmonary resuscitation, fibrinolysis, and successful salvage coronary angiography. However, he presented severe rhabdomyolysis associated with atorvastatin that required suspension of the drug and multi-organ support in a Coronary Care Unit. Conclusions: The prevalence of statin-associated rhabdomyolysis is low, however, the late elevation of CPK above 10 times its upper normal value in those patients with successful percutaneous coronary angiography should promptly draw attention, generate a diagnostic approach towards non-traumatic acquired causes of rhabdomyolysis and assess the suspension of statins.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionRhabdomyolysisAtorvastatinHumansMaleMiddle AgedRisk FactorsAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionRhabdomyolysis

Identifiers

PMID37207311
PMCPMC10395881
OpenAlexW4377142803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.